Organisation paid for research Program year 2021 Source: CMS Open Payments

Accellecare

Neither a doctor nor a teaching hospital

Research payments

$66,316

171 payments

Through program year 2021, Accellecare is reported as receiving $66,316 in research payments, across 171 payments.

By program year

1 row

Year	Kind	Amount	Payments
2021	Research	$66,316	171

Breakdown

Who paid Research payments · program year 2021

AstraZeneca Pharmaceuticals LP $60,978 12 payments
Novartis Pharmaceuticals Corporation $4,016 2 payments
Novo Nordisk AS $1,211 156 payments
AstraZeneca UK Limited $111 1 payment

Studies the money was for Research payments · program year 2021

A Phase II, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of MEDI3506 in Adult Participants with Uncontrolled Moderate to severe Asthma $22,173 1 payment
Randomised Parallel Double Blind Placebo Controlled Phase 2b Study to Assess the Safety Tolerability and Efficacy of AZD8233 Treatment in Participants with Hyperlipidaemia SOLANO $10,086 2 payments
An Observational Non interventional Study in Hyperlipidaemic Patients on Lipid Lowering Therapy OSTRO $9,329 1 payment
A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyposis WAYPOINT $6,283 2 payments
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) $4,374 2 payments
Long Term Prospective Multinational Parallel Cohort Study Monitoring Safety in Patients With Multiple Sclerosis Newly Started With Fingolimod Once Daily Or Treated With Another Approved Disease Modifying Therapy $3,819 1 payment
An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) $3,744 1 payment
A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer $2,990 2 payments
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab for the Prevention of Recurrence of Nasal Polyps Following Surgical Removal in Patients with Chronic Rhinosinusitis with Nasal Polyps (OXALIS) $2,000 1 payment
Nn9535-4533 $1,211 156 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.